Molecular Partners Ag (MOLN) Net Cash Flow (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Net Cash Flow of -$23577.3 for Q1 2026, down 220.57% year-over-year from $19554.5 in Q1 2025, and down 100.09% quarter-over-quarter from $25.2 million in Q4 2025.
Molecular Partners Ag (MOLN) Net Cash Flow (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Net Cash Flow for 7 consecutive years, with -$23577.3 the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow fell 220.57% year-over-year to -$23577.3; the TTM figure through Mar 2026 stood at $24.3 million (up 607.47% YoY), while the FY2025 annual figure was $25.2 million, up 610.0% from the prior year.
- Net Cash Flow eased to -$23577.3 in Q1 2026 per MOLN's latest filing, from $25.2 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $42.5 million in Q2 2022 and bottomed at -$42.5 million in Q3 2022.
- Historically, Net Cash Flow has averaged $1.1 million across 5 years, with a median of $300.17 in 2024.
- On a YoY basis, Net Cash Flow climbed as much as 6414.49% in 2025 and fell as far as 906.76% in 2025.
- Molecular Partners Ag's Net Cash Flow stood at $16.5 million in 2022, then plunged by 206.12% to -$17.5 million in 2023, then jumped by 71.76% to -$4.9 million in 2024, then jumped by 609.73% to $25.2 million in 2025, then tumbled by 100.09% to -$23577.3 in 2026.
- Business Quant data shows MOLN's Net Cash Flow at -$23577.3 in Q1 2026, $25.2 million in Q4 2025, and -$24.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.72 Bn | 77.73 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.93 Bn | 59.75 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 225.59 Mn |
| 10 | Molecular Partners Ag | 163.99 Mn | 163.99 Mn | - | -23,577.34 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23,577.34 |
| Mar 31, 2026 | -23,577.34 |
| Dec 31, 2025 | 25.18 Mn |
| Dec 31, 2025 | 25.18 Mn |
| Sep 30, 2025 | -23.99 Mn |
| Sep 30, 2025 | -23.99 Mn |
| Jun 30, 2025 | 23.18 Mn |
| Jun 30, 2025 | 23.18 Mn |
| Mar 31, 2025 | 19,554.48 |
| Mar 31, 2025 | 19,554.48 |
| Dec 31, 2024 | -4.94 Mn |
| Dec 31, 2024 | -4.94 Mn |
| Sep 30, 2024 | 2.97 Mn |
| Sep 30, 2024 | 2.97 Mn |
| Jun 30, 2024 | -2.85 Mn |
| Jun 30, 2024 | -2.85 Mn |
| Mar 31, 2024 | 300.17 |
| Mar 31, 2024 | 300.17 |
| Dec 31, 2023 | -17.49 Mn |
| Dec 31, 2023 | -17.49 Mn |